Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Enduring antibody response observed after natural immunity and first Pfizer SARS-CoV-2 vaccine shot

Immunity gained after natural infection from the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is boosted when people take the first Pfizer-BioNTech vaccine, according to a new study led by Iain C. Chapple from the University of Birmingham.

1 Mar 2021

Study: Repurposed arthritis drug did not improve outcomes of patients with severe COVID-19 pneumonia

In a study published online February 25, 2021 in The New England Journal of Medicine, a repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia.

1 Mar 2021

Researchers develop mutant gene-targeted immunotherapy approach to fight cancers

A novel targeted immunotherapy approach developed by researchers at the Ludwig Center, the Lustgarten Laboratory, and Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center employs new antibodies against genetically altered proteins to target cancers.

1 Mar 2021

Researchers evaluate surrogate large-scale SARS-CoV-2 serosurveillance test

A team of international scientists has recently evaluated a surrogate virus neutralization test for severe acute respiratory coronavirus 2 (SARS-CoV-2) and observed that it is highly efficacious for detecting anti-SARS-CoV-2 neutralizing antibodies in serum samples. According to the scientists, the test can be effectively used for population-level serosurveillance and evaluation of vaccine efficacy. The study is currently available on the medRxiv* preprint server.

1 Mar 2021

Single-dose of BNT162b2 vaccine may not be protective without prior SARS-CoV-2 infection

A new study by researchers at Imperial College London, UK, discusses the effect of a vaccine dose, specifically the BNT162b2 candidate (also known as the ‘Pfizer-BioNTech’ vaccine), on neutralizing antibody titers in individuals who have already been infected with the virus.

1 Mar 2021

One in seven people in England show SARS-CoV-2 antibodies, finds study

The REal-time Assessment of Community Transmission-2 (REACT-2) program completed its fifth round of community surveys in the days between January 26 and February 8, 2021. The findings appear in a new article in the BMJ on February 25, 2021, showing that natural infection and vaccination together account for around 14% seropositivity rates in England at present.

1 Mar 2021

Could SARS-CoV-2 antibody tests before first vaccine dose help increase coverage and protection?

A new study by scientists in the UK raises the very useful hypothesis that natural infection may help spread the vaccine thinner without loss of efficacy.

1 Mar 2021

New SARS-CoV-2 B.1.526 variant emerges in New York

New York has the first case of a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant called B.1.526, picked up by genomic surveillance research from Columbia University. The findings come after reports of other variants have been reported worldwide — B.1.1.7 in the United Kingdom, B.1.351 in South Africa, and P.1/P.2 in Brazil.

28 Feb 2021

Free-ranging minks exhibit high titers of SARS-CoV-2 antibodies in Utah

Researchers at the U.S. Centers for Disease Control and Prevention (CDC) report outbreaks of coronavirus disease (COVID-19) on mink farms in Utah, United States. They surveyed around farms for evidence of exposure and found high SARS-CoV-2 titers, suggesting a possible viral transmission pathway to native wildlife.

28 Feb 2021

FDA undertakes new action in its ongoing response effort to COVID-19 pandemic

The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:

27 Feb 2021

NLRP3 inflammasome inhibitors may help treat early COVID-19, says study

A new study by researchers in the U.S. further supports the hypothesis that the unregulated release of inflammatory cytokines is responsible for the local and systemic inflammation that is associated with multi-organ damage and death in severe COVID-19.

26 Feb 2021

South African SARS-CoV-2 variant partly resistant to neutralization by mRNA vaccine, says study

A new study deals with the clinical and virological effects of circulating SARS-CoV-2 variants, especially as they affect vaccine efficacy.

26 Feb 2021

Researchers develop new tool for predicting the effects of SARS-CoV-2 missense variants

A new study by a team of researchers in the UK and US describes the use of a computational tool that generates all possible single amino acid substitutions in SARS-CoV-2 and predicts their effects.

26 Feb 2021

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Researchers have developed a stable and ultrapotent homotrimeric Pittsburgh inhalable Nanobody 21 (PiN-21) against SARS-CoV-2 infection in Syrian hamsters. They demonstrated the high therapeutic efficacy of this homotrimeric Nb, leveraging both intranasal and aerosol delivery.

26 Feb 2021

Why Astrazeneca and J&J’s vaccines, in use the world over, are still on hold in America

The World Health Organization greenlighted emergency use of AstraZeneca and Oxford's covid-19 vaccine this month, following in the steps of the United Kingdom, the European Union and others, who are already injecting it as quickly as possible into the masses.

26 Feb 2021

Is one dose of Pfizer-BioNTech mRNA vaccine for COVID-19 convalescents sufficient?

Researchers evaluated the immune response in a cohort of 1,089 healthcare workers who received the Pfizer-BioNTech vaccine in Southern California.

26 Feb 2021

Biden’s straight-talking CDC director has long used data to save lives

In early December, Dr. Katy Stephenson was watching TV with her family and scrolling through Twitter when she saw a tweet that made her shout.

26 Feb 2021

Researchers investigate the duration of the immune response to SARS-CoV-2

The optimal timeframe for donating convalescent plasma for use in COVID-19 immunotherapy, which was given emergency use authorization by the Food and Drug Administration in August 2020, is within 60 days of the onset of symptoms, according to a new Penn State-led study.

26 Feb 2021

Programmed magnetic nanobeads rapidly diagnose COVID-19

COVID-19 can be diagnosed in 55 minutes or less with the help of programmed magnetic nanobeads and a diagnostic tool that plugs into an off-the-shelf cell phone, according to Rice University engineers.

26 Feb 2021

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

The first instance of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in Austria was observed in the Ski resort Ischgl in early March 2020. Later, the virus spread across Austria and other countries in Northern Europe.

25 Feb 2021

Antibody News and Research

Further Reading

Enduring antibody response observed after natural immunity and first Pfizer SARS-CoV-2 vaccine shot

Study: Repurposed arthritis drug did not improve outcomes of patients with severe COVID-19 pneumonia

Researchers develop mutant gene-targeted immunotherapy approach to fight cancers

Researchers evaluate surrogate large-scale SARS-CoV-2 serosurveillance test

Single-dose of BNT162b2 vaccine may not be protective without prior SARS-CoV-2 infection

One in seven people in England show SARS-CoV-2 antibodies, finds study

Could SARS-CoV-2 antibody tests before first vaccine dose help increase coverage and protection?

New SARS-CoV-2 B.1.526 variant emerges in New York

Free-ranging minks exhibit high titers of SARS-CoV-2 antibodies in Utah

FDA undertakes new action in its ongoing response effort to COVID-19 pandemic

NLRP3 inflammasome inhibitors may help treat early COVID-19, says study

South African SARS-CoV-2 variant partly resistant to neutralization by mRNA vaccine, says study

Researchers develop new tool for predicting the effects of SARS-CoV-2 missense variants

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Why Astrazeneca and J&J’s vaccines, in use the world over, are still on hold in America

Is one dose of Pfizer-BioNTech mRNA vaccine for COVID-19 convalescents sufficient?

Biden’s straight-talking CDC director has long used data to save lives

Researchers investigate the duration of the immune response to SARS-CoV-2

Programmed magnetic nanobeads rapidly diagnose COVID-19

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo